Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis

Current Chemical Biology Pub Date : 2021-01-21 DOI:10.2174/2212796815666210121095445

Zeba Mueed, P. Rai, S. Siddique, N. Poddar

{"title":"Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis","authors":"Zeba Mueed, P. Rai, S. Siddique, N. Poddar","doi":"10.2174/2212796815666210121095445","DOIUrl":null,"url":null,"abstract":"\n\nThe advancements in cancer treatment have no significant effect on\novarian cancer [OC]. The lethality of the OC remains on the top list of gynecological\ncancers. The long term survival rate of the OC patients with the advanced\nstage is less than 30%. The only effective measure to increase the survivability\nof the patient is the detection of disease in stage I. The earlier the diagnosis, the\nmore will be the chances of survival of the patient. But due to the absence of\nsymptoms and effective diagnosis, only a few % of OC are detected in stage I. A\nvalid, reliable having a high acceptance test is imperative to detect OC in its early\nstages. Currently, the most used approach for the detection of OC is the screening\nof CA-125 and transvaginal ultrasonography together. This approach has an\nefficacy of only 30-45%. A large number of biomarkers are also being explored\nfor their potential use in the early screening of OC, but no success is seen so far.\nThis review provides an overview of the biomarkers being explored for early-stage\ndiagnosis of OC and increasing the current long-term survival rates of OC\npatients.\n","PeriodicalId":10784,"journal":{"name":"Current Chemical Biology","volume":"20 1","pages":"109-125"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Chemical Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2212796815666210121095445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The advancements in cancer treatment have no significant effect on ovarian cancer [OC]. The lethality of the OC remains on the top list of gynecological cancers. The long term survival rate of the OC patients with the advanced stage is less than 30%. The only effective measure to increase the survivability of the patient is the detection of disease in stage I. The earlier the diagnosis, the more will be the chances of survival of the patient. But due to the absence of symptoms and effective diagnosis, only a few % of OC are detected in stage I. A valid, reliable having a high acceptance test is imperative to detect OC in its early stages. Currently, the most used approach for the detection of OC is the screening of CA-125 and transvaginal ultrasonography together. This approach has an efficacy of only 30-45%. A large number of biomarkers are also being explored for their potential use in the early screening of OC, but no success is seen so far. This review provides an overview of the biomarkers being explored for early-stage diagnosis of OC and increasing the current long-term survival rates of OC patients.

查看原文本刊更多论文

卵巢癌生物标志物:早期诊断的进展

癌症治疗的进展对卵巢癌没有显著影响[OC]。卵巢癌的致死率仍居妇科癌症之首。晚期OC患者的长期生存率低于30%。提高患者生存能力的唯一有效措施是在第一阶段发现疾病。诊断越早，患者生存的机会就越大。但由于缺乏症状和有效的诊断，只有极少数的OC在i期被发现。有效、可靠、高接受度的检测是在早期发现OC的必要条件。目前，检测卵巢癌最常用的方法是CA-125筛查和经阴道超声检查。这种方法的无效率只有30-45%。大量的生物标志物也在探索其在早期卵巢癌筛查中的潜在用途，但迄今为止尚未取得成功。本文综述了目前正在探索的用于卵巢癌早期诊断和提高卵巢癌患者长期生存率的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Chemical Biology Medicine-Biochemistry (medical)

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： Current Chemical Biology aims to publish full-length and mini reviews on exciting new developments at the chemistry-biology interface, covering topics relating to Chemical Synthesis, Science at Chemistry-Biology Interface and Chemical Mechanisms of Biological Systems. Current Chemical Biology covers the following areas: Chemical Synthesis (Syntheses of biologically important macromolecules including proteins, polypeptides, oligonucleotides, oligosaccharides etc.; Asymmetric synthesis; Combinatorial synthesis; Diversity-oriented synthesis; Template-directed synthesis; Biomimetic synthesis; Solid phase biomolecular synthesis; Synthesis of small biomolecules: amino acids, peptides, lipids, carbohydrates and nucleosides; and Natural product synthesis).